Cyclophosphamide in lupus nephritis: a controlled trial.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D001706:Biopsy; D002648:Child; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000032:analysis; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004247:DNA; D005260:Female; D006417:Hematuria / Q000150:complications; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007668:Kidney / Q000473:pathology; D007958:Leukocyte Count; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D009393:Nephritis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D009504:Neutrophils; D010919:Placebos; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011507:Proteinuria / Q000150:complications; D011776:Pyuria / Q000150:complications; D013997:Time Factors; D014556:Urine / Q000166:cytology; D005719:gamma-Globulins / Q000032:analysis
D000974:Antibodies, Antinuclear; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D010919:Placebos; D005719:gamma-Globulins; D003520:Cyclophosphamide; D003165:Complement System Proteins; D004247:DNA; D003404:Creatinine; D011241:Prednisone